773104-00-0

Basic information

• Product Name: Methyl 4-Methyl-3-thioureidobenzoate
• Synonyms: Methyl 4-Methyl-3-thioureidobenzoate
• CAS NO: 773104-00-0
• Molecular Formula: C₁₀H₁₂N₂O₂S
• Molecular Weight: 224.27948
• Mol File: 773104-00-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-Methyl-3-thioureidobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-Methyl-3-thioureidobenzoate(773104-00-0)
• EPA Substance Registry System: Methyl 4-Methyl-3-thioureidobenzoate(773104-00-0)

Safety Data

• Hazardous Substances Data: 773104-00-0(Hazardous Substances Data)

Upstream product

• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 333-20-0 potassium thioacyanate 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 1093071-59-0 3-[5-chloro-4-(2,4-difluorobenzyloxy)-6-oxo-6H-pyrimidin-1-yl]-N-[(R)-2-(2-methoxyethyl)-3-oxo-isoxazolidin-4-yl]-4-methylbenzamide 
• 1093071-71-6 C₂₀H₁₅ClF₂N₂O₅S 
• 1093071-70-5 C₂₀H₁₅ClF₂N₂O₆S 
• 944154-49-8 3-[5-chloro-4-(2,4-difluoro-benzyloxy)-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl]-4-methyl-benzoic acid 
• 773104-07-7 3-[5-chloro-4-(2,4-difluorobenzyloxy)-6-oxo-6H-pyrimidin-1-yl]-4-methylbenzoic acid 
• 773104-06-6 C₁₉H₁₄F₂N₂O₄ 
• 773104-02-2 methyl 3-[4-[(2,4-difluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate 
• 773104-01-1 3-(4-hydroxy-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-4-methyl-benzoic acid methyl ester 
• 1314804-46-0 C₂₂H₂₁F₂N₃O₄ 
• 1314804-45-9 C₂₁H₁₈F₂N₂O₄ 

Relevant articles and documents

Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitors

A novel series of highly potent and selective p38 MAP kinase inhibitors was developed originating from a substituted N-aryl-6-pyrimidinone scaffold. SAR studies coupled with in vivo evaluations in rat arthritis model culminated in the identification of 10 with excellent oral efficacy. Compound 10 exhibited a significantly enhanced dissolution rate compared to 1, translating to a high oral bioavailability (>90%) in rat. In animal studies 10 inhibited LPS-stimulated production of tumor necrosis factor-α in a dose-dependent manner and demonstrated robust efficacy comparable to dexamethasone in a rat streptococcal cell wall-induced arthritis model.

KINASE INHIBITOR COMPOUNDS

Pyrimidinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as inflammatory diseases and certain types of cancer.

PYRIMIDINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Pyrimidinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as inflammatory diseases and certain types of cancer.

2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS

The present invention relates to novel compounds selected from 2-(3-substitutedaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a va

SUBSTITUTED PYRIMIDINONES

Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

P-38 inhibitors

Provided are 5-membered heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.